Stockscreener 앱 받기
12.30
1.76%
-0.22
시장 영업 전:
11.94
-0.36
-2.93%
Neuropace Inc 주식(NPCE)의 최신 뉴스
Head-To-Head Review: NeuroPace (NASDAQ:NPCE) vs. Aethlon Medical (NASDAQ:AEMD) - Defense World
Cantor Fitzgerald Forecasts Lower Earnings for NeuroPace - MarketBeat
Morgan Stanley Reduces Stake in NeuroPace Inc: A Strategic Portf - GuruFocus.com
JPMorgan Chase & Co. Has $84,000 Holdings in NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
Wells Fargo & Company Issues Positive Forecast for NeuroPace (NASDAQ:NPCE) Stock Price - MarketBeat
NeuroPace, Inc. to Present Findings on RNS System for Focal Epilepsy at AAN 2025 Annual Meeting - Nasdaq
NeuroPace Announces Upcoming Oral Presentation of Data from the Post-Approval Study of the RNS System at the American Academy of Neurology 2025 Annual Meeting Being Held April 5th9th - The Manila Times
Major Epilepsy Treatment Breakthrough: NeuroPace's RNS System Data Coming to AAN 2025 - StockTitan
Leerink Partnrs Estimates NeuroPace FY2029 Earnings - MarketBeat
NeuroPace, Inc. (NASDAQ:NPCE) Insider Martha Morrell Sells 3,200 Shares - MarketBeat
NeuroPace FY2025 EPS Forecast Reduced by Cantor Fitzgerald - Defense World
Wells Fargo & Company Boosts NeuroPace (NASDAQ:NPCE) Price Target to $17.00 - Defense World
Leerink Partnrs Predicts NeuroPace FY2029 Earnings - Defense World
NeuroPace's SWOT analysis: epilepsy device maker's stock poised for growth - Investing.com India
NeuroPace’s SWOT analysis: epilepsy device maker’s stock poised for growth By Investing.com - Investing.com Nigeria
Neuropace chief medical officer Morrell sells $48,032 in stock - MSN
NeuroPace Expects 2025 Revenue Growth -January 29, 2025 at 03:36 am EST - Marketscreener.com
Neuropace chief medical officer Morrell sells $48,032 in stock By Investing.com - Investing.com Australia
NeuroPace Projects 2025 Growth and Product Enhancements - TipRanks
NeuroPace Issues 2025 Financial Guidance Targets - The Manila Times
NeuroPace Issues 2025 Financial Guidance Targets -January 28, 2025 at 05:16 pm EST - Marketscreener.com
NeuroPace's Bold Plan to Transform Epilepsy Treatment: AI, New Markets, and 20% Growth - StockTitan
How the (NPCE) price action is used to our Advantage - Stock Traders Daily
NeuroPace, Inc. (NASDAQ:NPCE) Looks Just Right With A 26% Price Jump - Simply Wall St
Cantor Fitzgerald Comments on NeuroPace FY2025 Earnings - Defense World
Cantor Fitzgerald Predicts NeuroPace FY2025 Earnings - MarketBeat
UBS Group Begins Coverage on NeuroPace (NASDAQ:NPCE) - Defense World
Barclays PLC Buys 16,007 Shares of NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
NeuroPace (NPCE) Soars 9.1%: Is Further Upside Left in the Stock? - Yahoo Finance
UBS sees upside for NeuroPace shares with 22% CAGR and market expansion drivers - Investing.com Australia
NeuroPace (NASDAQ:NPCE) Now Covered by Analysts at UBS Group - MarketBeat
Kck Ltd. Purchases Shares of 5,270,845 NeuroPace, Inc. (NASDAQ:NPCE) - MarketBeat
NeuroPace, Inc. (NASDAQ:NPCE) Receives $15.00 Average Target Price from Brokerages - Defense World
NeuroPace to Present at J.P. Morgan Healthcare Conference - TipRanks
NeuroPace, Inc. (NASDAQ:NPCE) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
NeuroPace's SWOT analysis: epilepsy device maker's stock poised for growth By Investing.com - Investing.com Australia
NeuroPace reports preliminary Q4 revenue - MSN
0.38%
1.34%
자본화:
|
볼륨(24시간):